Investor Presentation

June 2017

Safe Harbor StatementThis presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the safe harbor provisions of the

U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include all statements that are not

historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey

uncertainty of future events or outcomes and the negatives of those terms. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive

position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Such statements involve a number of known and unknown risks and uncertainties that could cause our future

results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Some of the important factors that could cause or contribute to such

differences include the following: a high proportion of the sales of the INFAT® product is to our customers who then use it in their infant formula products sold to end users in China and therefore our revenues are subject to the effects of

Chinese market trends and competition from locally produced products that are not subject to import taxes; we are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments

with us; new Chinese regulations relating to infant formula came into force on October 2016 and others are constantly evaluated, affecting the ability of our customers to market infant nutrition products containing INFAT®, which could

adversely affect our revenues and results of operations; we rely on our Swedish joint venture partner to manufacture INFAT®; growth in the Chinese economy has moderated and this slowdown and related volatility could adversely impact

demand for our products in China; the demand for products based on omega-3, and, in particular, premium products such as krill oil, has declined in the past and may continue to decline, which, together with a significant increase in

capacity by competing manufacturers, may continue to cause intense competition and price pressures; Chinese regulations relating to infant formula are under re-examination, and any regulatory changes affecting the ability of our

customers to market infant nutrition products containing INFAT® could adversely affect our business; our inventories include sensitive compounds which may face spoilage or obsolescence; our inability to manage our inventory levels, in

particular our high level of inventory relative to sales of our products, may have an adverse effect on our profitability; a significant portion of the sales of our INFAT® product is to a small number of customers and if such customers were to

suffer financially or reduce its use of INFAT® our business could be materially adversely affected; the demand for premium products based on omega-3, and, in particular, krill oil, has declined in the past and may decline in the future, which

may result in intense competition and price pressure; variations in the cost of raw materials for the production of our products may have a material adverse effect on our business, financial condition and results of operations; our offering

of products as "medical foods" may be challenged by regulatory authorities; the outcome of the Company's discussions with the FDA relating to the Import Alert; our product development cycle is lengthy and uncertain, and our

development or commercialization efforts for our products may be unsuccessful; we are dependent on a single facility that houses the majority of our operations, and disruptions at this facility could negatively affect our business, financial

condition and operations; we depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products and if we cannot secure sufficient supply sources at competitive prices or need to utilize a

greater percentage of frozen krill than anticipated with current inventory levels, our gross profits from the sale of krill oil will be adversely affected; we anticipate that the markets in which we participate will become more competitive due

in part to business combinations among existing competitors, the arrival of new competitors and technological developments; our results are subject to quarterly fluctuations; we may have to pay royalties with respect to sales of our krill oil

products in the United States or Australia, and any infringement of intellectual property of others could require us to pay royalties; unfavorable publicity or consumer perception of our products, such as krill oil, the supplements that

contain them as ingredients and any similar products distributed by other companies could have a material adverse effect on our reputation, the demand for our products and our ability to generate revenues; we are generally reliant upon

third parties for the distribution or commercialization of our products; we may not be able to maintain or increase market acceptance for our products; we are subject to risks relating to the operation and expansion of our production or

processing facilities and capabilities; our ability to obtain krill may be affected by conservation regulation or initiatives; disruption to our IT system could adversely affect our reputation and have a material adverse impact on our business

and results of operations; we are not able to predict the results of clinical trials, which may prove unsuccessful or be delayed by certain factors; if we are unable to maintain manufacturing efficiency and quality and meet our customers’

needs, our financial performance could be adversely affected; we could be subject to product liability lawsuits, which could result in costly and time-consuming litigation and significant liabilities; our dependence on international sales,

which expose us to risks associated with the business environment in those countries; and other factors discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 filed with the

Securities and Exchange Commission on March 16, 2017.

You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity,

performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to

update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

2

Enzymotec: At-A-Glance

• Listed on the NASDAQ: ENZY

• Leader in lipids technology with potential to collaborate with

complementary technologies to expand product offering

• Fully integrated platform from R&D to manufacturing

• Recently appointed CEO developing growth strategy with

$73.8 million net cash on balance sheet

• Large market opportunity within multiple high value

applications

• Significant geographic expansion opportunities leveraging

existing worldwide footprint

3

Fully Integrated Platform

4

Manufacturing

Process Development

Lipid TechnologyEnzymatic Technology

Research and Development

B2B2C

IPClinical

Support

Regulatory

Expertise

Key Facts & Figures

5

Globalpresence in over

30countries

12Successfully completed

randomized pivotal controlled clinical trials

26Peer-reviewed

articles

Provenregulatory

track record

Diversesuite of

15products

Robust IPportfolio of over

200patents & patent

applications

220Employees

State-of-the-art

GMP-compliant facility in Israel

The Biological Importance of Lipids

04

03

02

01

Major structural components of all

cell membranes - key to important

biological functions, including cell

to cell communication

~60,000 different types in the

human body and ~60% of the

brain's dry mass consists of lipids -

Play an essential role in nerve cell

development, survival and proper

function

Deficiencies or imbalances in lipid

levels are associated with a wide

array of diseases and disorders

Only limited research in the field of

lipids despite crucial role in tissue

physiology, cell signaling, and

associated disorders

Unique

Process

High Value

Applications Consumer Health

and Wellness

Products

Natural

ResourcesRaw krill, Fish,

Vegetable

sources, Bovine

milk, Others

6

High Value Applications

Enzymotec’s

Lipid

TechnologyBioactive

Ingredients

VAYA

PHARMA

Infant

Nutrition

Premium infant formula

ingredients that resemble

composition and properties of

human breast milk fat

Revenues: $10.1M**

Value-added ingredients for

nutritional supplement

companies

Revenues: $4.2M*

Lipid-based, branded medical

foods for dietary management of

cardiovascular and neurological

conditions sold primarily in the

U.S. under physician supervision

Revenues: $2.7M*

7

Nu

tritio

n D

ivis

ion

* 1Q 2017

** Proportionate Consolidation Method

Large and Growing Infant Formula Market

China, 18814

Indonesia, 2270

USA, 4913

Thailand, 729

France, 724

Vietnam, 1187

UK, 665

Spain, 304

Hong Kong, 2571

Russia, 555

Argentina, 254

Mexico, 838

Brazil, 450

Germany, 391

Malaysia, 386

Turkey, 212

Saudi Arabia, 690India, 260

Italy, 272Canada, 285

Japan, 523

S.Africa, 213

Australia, 372

S. Korea, 368

-15

-10

-5

0

5

10

15

20

25

30

35

40

Source: Euro monitor 2015

* Average CAGR 2010-2015

135 million infants born annually

$41 billion retail value

45% from China

Average Global CAGR*: 10.02%

China’s CAGR: 19.02%

SEA CAGR: 12.8%

USA CAGR: 2.72%

8

INFAT: Marketed by Advanced Lipids*

9

Infant Formula Oils Market

Volume (MT)

Other

Oils

(>90%)

sn-2

palmitate

(<10%)

Enzymatic Process

OP

O

P

P

O

Vegetable OilINFAT

sn-2 palmitate

Human Breast Milk Fat

One Step Closer to Human

Breast Milk

P O Oleic AcidPalmitic Acid

* Advanced Lipids is a joint venture of Enzymotec and AarhusKarlshamn (AAK)

Ireland Dairy Milk BeingMateFEIHE Biostime Yashili

1.6M

Unmet Need in U.S. - Medical Food for CNS

Adolescent ADHD

Pediatric ADHD

3.1M

Mild Cognitive Impairment

8.3M

Autism

800K

Adult ADHD

10.2M

Category of Regulation Defined by FDA

Intended for use under a physician's

supervision

Nutritional deficiency correlated with

diseases

Unavailable via regular diet

• Specially formulated

• Based on recognized scientific

principles

• Produced under current Good

Manufacturing Practices (cGMP)

Contains ingredients that are Generally

Recognized As Safe (GRAS)

10

VAYA’s Growth Towards Profitability

• Increase productivity of sales representatives

• Continue to improve refill and compliance rates through online pharmacy and call center

• Develop patient support groups to further engage customers and their dietary programs

• Expand clinical indications with additional clinical trials

• Develop strategic partnerships outside the U.S.

• Increase awareness of clinical advantages among US healthcare professionals

• Leverage connections with physicians to generate new ideas

11

Global Supplement Market

25%

9%

7%

10%17%

32%

Specialty/Other Meal supplements

Minerals Sports supplements

Herbs/Botanicals Vitamins

• $35 billion* Global Dietary Supplements

Market (raw materials)

• $8.75 billion Specialty/Other Market share -(Enzymotec current domain)

• Added value ingrediencies (Specialty, Meal

Supplements, Minerals and Sport Supplements) is 50%of total market

Global Ingredient Value

$80M*Global Ingredient Value

$65M*

* Estimate

12

BioActive Growth Opportunities

13

Recapture Market Share

New Product Launches

Consolidation Opportunities

New Contracts

Variety of Grades

New Target Markets

New Product Launches

New Partnerships

Enzymotec’s Growth Opportunities

New product

launches

New strategic partnershipsNew regulatory

environment in China

Geographic

expansionNew applications for

lipids technology

Grow patient/

customer base

Bioactive

Ingredients

VAYA

PHARMA

Infant

Nutrition

14

Key Financials

15

*Proportionate Consolidation Method

$61.5 $62.6 $60.9

$17.1

$0.0

$10.0

$20.0

$30.0

$40.0

$50.0

$60.0

$70.0

FY 2014 FY 2015 FY 2016 1Q17

$ in

mil

lio

ns

Net Revenues*

Margins

$14.0 $13.9 $12.5

$4.0

$11.4 $10.7

$4.2

$1.5

$0

$5

$10

$15

2014 2015 2016 1Q17

25% 19% 26% 17% 25% 7%

Adjusted EBITDA

Nutrition

Consolidated

Quarterly

28% 9%

Solid Financials

16

Generated

$1.5 million

in adjusted

EBITDA in

1Q 2017

Strong net

cash position

of $73.8

million*

No Debt

Significant

conversion

of EBITDA to

net income

Tax

exempt in

Israel

until 2022

Reduced

capital

expenditures

and D&A

Crafting a New Strategy

17

Strengthen Foundation

Leverage Opportunities

Drive Growth

• Market Expansions • Product Expansions

• Leverage Salesforce • $73.8M net cash

• Enhance capabilities in Sales & Marketing,

Operations and Finance

• Reinforce science

• Expand branding

• Add new, innovative products

• Optimize VAYA

• Organically

• Inorganically

New Leadership

THANK

YOU

www.enzymotec.com